Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that final results from the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3 clinical trial were published in the August 11, 2007, issue of The Lancet. The study suggests that treatment with Kuvan results in significant reductions in blood Phe levels in some phenylketonuria (PKU) patients. Kuvan, an investigational oral small molecule for the treatment of PKU, is being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

"This marks the first published Kuvan clinical study, and we expect additional publications in the coming months to build on the collection of data related to Kuvan," said Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin. "We recently received priority review from the FDA and hope to receive FDA approval by late November. In the interim, we are pleased to be able to provide Kuvan to PKU patients prior to commercial availability through our expanded access program."

The Phase 3 clinical study enrolled 89 patients with elevated blood Phe levels aged eight years and above at 29 sites in the United States, Europe and Canada. All patients enrolled had demonstrated a reduction in blood Phe levels following treatment with Kuvan in a Phase 2 screening study.

The patients were randomly assigned to receive placebo or 10 mg/kg of Kuvan daily for six weeks. Patients were evaluated every two weeks for changes in blood Phe levels and adverse events. The primary objective was to assess the efficacy of Kuvan compared with placebo for reduction of blood phenylalanine in patients with PKU. The secondary objective was to assess the safety of Kuvan compared with placebo. A total of 87 patients completed six weeks of treatment.

Highlights from the Phase 3 double-blind study are summarized below:

* Patients treated with Kuvan for six weeks had a mean decrease
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... Tenn. , Dec. 22, 2014   TRU-D ... automated, no-touch UV disinfection robot, announced today that the ... Schedule contract through November 2019.   This ... rapidly engage all levels of government purchasers, including Department ... as well as Homeland Security contacts purchasing solutions for ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... SATURDAY, May 7 (HealthDay News) -- Many women wear high ... shoes can cause foot problems such as hammertoe, a condition ... experts warn. Dr. Tzvi Bar-David, a podiatrist at New ... on how to keep their feet comfortable without sacrificing fashion. ...
... (HealthDay News) -- Mutations in a single gene have a ... cerebral cortex, the part of the brain that plays a ... and consciousness. That,s the finding of a new study ... one Turkish, two Pakistani -- with children that have the ...
... CA May 6, 2011 Researchers at The Scripps Research ... tripped, allows calcium to pour in and activate an immune response. ... fever, or when it fallssuch as when immune cells are "called" ... cooler skin. The study, recently published online ahead of print ...
... A new strain of Staphylococcus aureus bacteria associated with ... child care worker who reported no contact with livestock, ... was an unexpected finding in a study of Staphylococcus ... Moritz, a doctoral student in epidemiology in the UI ...
... May 6 (HealthDay News) -- Americans walked and biked a ... new research finds. But the increases were minor, especially ... in the American Journal of Public Health . ... 2009 U.S. National Household Travel Surveys and found that the ...
... , INDIANAPOLIS Specialized one- and two-year Indiana ... increase the number of health information technology specialists ... 50 percent, thanks in part to Recovery Act ... as distance learning opportunities. In collaboration with ...
Cached Medicine News:Health News:Doc Offers High-Heel Wearers Tips to Prevent 'Hammertoe' 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 3Health News:Study finds livestock-related 'Staph' strain in child care worker 2Health News:Americans Walking, Biking a Bit More, Research Shows 2Health News:IU-Regenstrief programs targeted to alleviate shortage of health IT workforce 2
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. Designated most popular model or size....
Medicine Products: